Cochlear grew out of the Australian invention of the bionic ear, and is now the world’s leading maker of hearing implants. Here’s how it makes its money.
Cochlear is the world’s largest maker of implantable hearing devices, and one of the biggest health companies on the ASX.
It grew out of the work of Professor Graeme Clark at the University of Melbourne, who developed the multi-channel cochlear implant, often called the bionic ear. The first patient received one in 1978. Cochlear was set up in 1981 to commercialise the technology, and listed on the ASX in 1995. It is based at Macquarie University in Sydney, reports in Australian dollars, and its financial year ends on 30 June.
Implants
A cochlear implant is surgically placed under the skin behind the ear, and sends electrical signals directly to the hearing nerve. It is used by people with severe to profound hearing loss who get little benefit from hearing aids. A sound processor worn on the head picks up sound and sends it to the implant.
Implants are Cochlear’s biggest business. It sells them to hospitals and health systems, and they are often paid for by governments or insurers.
Most of its sales are in developed countries, but it is growing in emerging markets, where prices are lower.
Upgrades and acoustics
Once someone has an implant, they typically upgrade their sound processor every few years, as new technology comes out. These upgrades give Cochlear a valuable, recurring source of income from its large base of existing users.
Cochlear also sells acoustic implants, which work by conducting sound through bone, for people with other types of hearing loss.
Its newest implant, Nucleus Nexa, launched in 2025, is the first with upgradeable software inside the implant itself.
The risks
Cochlear has only a few competitors, but it must keep investing heavily in research to stay ahead. The risks include competition, lower prices in emerging markets, changes to government and insurer funding, slower uptake of upgrades, and currency movements, as most of its sales are overseas.
Latest results, as at 9 November 2026
Full year to June 2026, reported 18 August 2026: sales rose 2 per cent in constant currency to $2.34 billion. Underlying profit fell 22 per cent to $322 million, at the top of its lowered forecast, as gross margins fell and research spending rose 15 per cent. Total dividends fell 20 per cent to $3.45 a share.
For the 2027 financial year, Cochlear expects underlying profit of between $330 million and $350 million.
Next update: Cochlear reports its half-year results, to December 2026, in February 2027.























Comments
No comments yet. Start the conversation.